Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 35 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Keyword is Imidazoles  [Clear All Filters]
Journal Article
Anastasilakis, A. D., Polyzos S. A., Makras P., Sakellariou G. T., Bisbinas I., Gkiomisi A., et al. (2012).  Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.. Bone. 50(5), 1130-4.
Bantis, A., Zissimopoulos A., Sountoulides P., Kalaitzis C., Giannakopoulos S., Deftereos S., et al. (2011).  Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies.. Tumori. 97(4), 479-83.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Sujobert, P., Poulain L., Paubelle E., Zylbersztejn F., Grenier A., Lambert M., et al. (2015).  Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.. Cell Rep. 11(9), 1446-57.
Kyrgidis, A., & Triaridis S. (2009).  Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.. Oral Oncol. 45(6), e38; author reply e39.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Anastasilakis, A. D., Polyzos S. A., Efstathiadou Z. A., Savvidis M., Sakellariou G. T., Papatheodorou A., et al. (2015).  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.. Metabolism. 64(10), 1291-7.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Saridakis Z. G., Digkas D., Bisbinas I., et al. (2015).  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.. Osteoporos Int. 26(10), 2521-7.
Polyzos, S. A., Anastasilakis A. D., Litsas I., Sapranidis M., Efstathiadou Z., Kita M., et al. (2010).  Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.. J Clin Densitom. 13(2), 190-6.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z., Kita M., Litsas I., Avramidis A., et al. (2009).  The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.. Horm Metab Res. 41(11), 846-50.
Dimitriadis, F., Tsampalas S., Tsounapi P., Giannakis D., Chaliasos N., Baltogiannis D., et al. (2012).  Effects of phosphodiesterase-5 inhibitor vardenafil on testicular androgen-binding protein secretion, the maintenance of foci of advanced spermatogenesis and the sperm fertilising capacity in azoospermic men.. Andrologia. 44 Suppl 1, 144-53.
Dimitriadis, F., Tsambalas S., Tsounapi P., Kawamura H., Vlachopoulou E., Haliasos N., et al. (2010).  Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial.. BJU Int. 106(8), 1181-5.
Zarogoulidis, K., Boutsikou E., Zarogoulidis P., Eleftheriadou E., Kontakiotis T., Lithoxopoulou H., et al. (2009).  The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.. Int J Cancer. 125(7), 1705-9.
Kyrgidis, A., Yavropoulou M. P., Lagoudaki R., Andreadis C., Antoniades K., & Kouvelas D. (2017).  Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.. Osteoporos Int. 28(3), 991-999.
Ooi, M. G., Hayden P. J., Kotoula V., McMillin D. W., Charalambous E., Daskalaki E., et al. (2009).  Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.. Clin Cancer Res. 15(23), 7153-60.
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
Vahtsevanos, K., Kyrgidis A., Verrou E., Katodritou E., Triaridis S., Andreadis C. G., et al. (2009).  Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.. J Clin Oncol. 27(32), 5356-62.
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Shimizu, S., Saito M., Oiwa H., Ohmasa F., Tsounapi P., Oikawa R., et al. (2014).  Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.. Neurourol Urodyn. 33(3), 350-7.
Oikonomou, A., Birbilis T., Gymnopoulou E., & Prassopoulos P. (2007).  Paget disease of the spine manifested by thoracic and lumbar epidural lipomatosis: magnetic resonance imaging findings.. Spine (Phila Pa 1976). 32(25), E789-92.
Tziomalos, K., Florentin M., Krikis N., Perifanis V., Karagiannis A., & Harsoulis F. (2007).  Persistent effect of zoledronic acid in Paget's disease.. Clin Exp Rheumatol. 25(3), 464-6.
Apalla, Z., Tzellos T., Lallas A., Sotiriou E., & Lefaki I. (2012).  Possible zoledronic acid-induced dermatomyositis.. Clin Exp Dermatol. 37(3), 309-11.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές